Vestion develops tissue regenerative therapies for a variety
of disease states. Our lead products are
cell therapies designed to be delivered to the heart via a minimally invasive
catheter technique. Preclinical and
clinical trial evidence indicate that this approach can improve heart muscle
function even decades after damage caused by a heart attack.
Vestion will commercialize proprietary cell types and
products. The first of these is designed
for the safe and highly efficient treatment of diseased heart muscle. Both allogeneic (donor cells) and autologous
(patient’s own cells) therapies are supported by Vestion’s cell processing
If you'd like to get notified of updates, let us know.